This will be a 2-part, randomized, participant- and investigator-blind study in healthy males
and females.
Part A of this study is to determine a safe and tolerable single oral dose of LY3009104 that
yields drug exposures slightly exceeding typical exposures anticipated from repeated
administration of an efficacious dose to participants. The concentration of the drug in the
blood stream will be measured and information about any side effects that may occur will also
be collected.
Part B of this study is to evaluate the effect of LY3009104 on the electrical activity of the
heart as measured by electrocardiogram (ECG) in relation to placebo following a single oral
dose.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Incyte Corporation
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination